123I‐metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra‐adrenal phaeochromocytomas: CT and MRI correlation
- 15 July 2008
- journal article
- research article
- Published by Wiley in Clinical Endocrinology
- Vol. 69 (2) , 181-188
- https://doi.org/10.1111/j.1365-2265.2008.03256.x
Abstract
Context Evidence regarding the accuracy of [123I] metaiodobenzylguanidine (MIBG) imaging for phaeochromocytoma localization is currently limited to small series. Objective We present the largest series of primary phaeochromocytomas in which the performance of [123I]MIBG has been evaluated and correlated with cross‐sectional imaging. Design We identified 76 patients with both preoperative [123I]MIBG and cross‐sectional imaging for confirmed primary phaeochromocytoma between 1995 and 2005 at our institution. This comprised 60 adrenal tumours in 55 patients and 33 extra‐adrenal tumours in 23 patients (2 patients had both adrenal and extra‐adrenal tumours). Phaeochromocytoma metastases were not evaluated. Main outcome measure(s) [123I]MIBG studies were independently reviewed and correlated with CT and MRI examinations, as well as tumour functional status, to identify features that may predict a false negative [123I]MIBG result. Results The overall sensitivity of [123I]MIBG was 75%. Tumour detection was lower for extra‐adrenal (58%) vs. adrenal (85%) phaeochromocytomas (P = 0·005). For extra‐adrenal tumours, [123I]MIBG demonstrated 8 of 14 carotid body, 2 of 2 intrathoracic, 8 of 14 retroperitoneal and 2 of 3 pelvic phaeochromocytomas. Overall, MRI and CT demonstrated 68 of 68 and 72 of 74 primary phaeochromocytomas, respectively. Tumour size correlated with [123I]MIBG uptake for adrenal (P = 0·009) but not extra‐adrenal tumours. When tumours were adjusted for size, no other imaging feature or functional status correlated with [123I]MIBG negativity, although two large [123I]MIBG negative adrenal tumours contained large areas of necrosis or haemorrhage. Conclusions Extra‐adrenal and small adrenal phaeochromocytomas are more likely to result in false negatives on [123I]MIBG. Tumoural necrosis or haemorrhage do not consistently relate to [123I]MIBG uptake, although adrenal phaeochromocytomas containing minimal solid tissue due to extensive necrosis may predict a negative [123I]MIBG result.Keywords
This publication has 26 references indexed in Scilit:
- Effectiveness and limits of preoperative imaging studies for the localisation of pheochromocytomas and paragangliomas: a review of 282 casesBritish Journal of Surgery, 2003
- Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomasJournal of Internal Medicine, 2001
- Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography (CT) in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomasJournal of Internal Medicine, 2001
- Limited Role of Meta-iodobenzylguanidine Scintigraphy in Imaging Phaeochromocytoma in Patients with Multiple Endocrine Neoplasia Type IIThe European Journal of Surgery, 2000
- Diagnosis of pheochromocytoma using [123I]‐ compared with [131I]‐metaiodobenzylguanidine scintigraphyInternational Journal of Urology, 1999
- Location of Adrenal Medullary Pheochromocytoma By l-123 Metaiodobenzylguanidine SPECTClinical Nuclear Medicine, 1996
- Iodine 131-labeled metaiodobenzylguanidine scintigraphy and biochemical analyses in suspected pheochromocytomaArchives of internal medicine (1960), 1991
- Iodine-131 meta-iodobenzylguanidine (131I-MIBG) for the localization of suspected phaeochromocytomaNuclear Medicine Communications, 1989
- New approach to the localisation of phaeochromocytoma: imaging with iodine-131-meta-iodobenzylguanidine.BMJ, 1984
- SCINTIGRAPHIC LOCALIZATION OF PHAEOCHROMOCYTOMASClinical Endocrinology, 1984